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Abstract Acute ureteral obstruction leads to changes in
pressure inside the ureter, interrupting ureter function. The
aim of our study is to explore the relationship between
nitric oxide (NO) concentration and pressure in the ureter
and to observe the effects of nitric oxide on the revival of
renal function. We created the animal models by embed-
ding balloons in the lower ureters of anesthetized dogs and
expanding them to simulate acute ureteral obstruction.
First, the test animals were pre-treated intravenously with
different doses of L-NAME (non-selective nitric oxide
synthase inhibitor) to inhibit nitric oxide synthase (NOS),
and 10 min later, each subject was administered an intra-
venous dose of isoproterenol (10 lg/kg). We measured
ureter pressure (UP), total and peak concentrations of NO
(using an NO monitor, model inNO-T) in ureteral urine,
and the volume of the urine (UFV) leaking from the bal-
loon edge. After a certain amount of time had elapsed, it
became clear that the dose of L-NAME was inversely
related to the total and peak concentrations of NO, the rate
of change in UP, and the volume of urine produced. We
conclude that L-NAME prevents the NOS from inhibiting
the release of NO, then inhibits the effect of isoproterenol
reducing the pressure of the acute obstructive ureter.
Inversely, we think that NO can reduce the pressure of the
acute obstructive ureter and make the obstructive ureter
recanalization. And when more the concentration of nitric
oxide, the more the pressure will be reduced, and more
urine will be collected.
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Introduction
Acute ureteral obstruction is a common complication of
other conditions studied in clinical urology, such as urinary
tract stones, ureteropelvic junction obstruction (UPJO), and
the complete and incomplete ureteral obstruction caused by
postoperative tissues adhesion. Acute ureteral obstruction
leads to changes in pressure inside the ureter, interrupting
ureter function [1, 2].
Recent research has found that there are nitric oxide
synthases (NOS) existing in mammals’ ureteral smooth
muscle and urothelial tissues [3–5]. Activation of NOS can
stimulate the release of nitric oxide (NO). As an endothe-
lium-derived relaxing factor (EDRF), NO can cause the
vascular smooth muscle to relax, thereby reducing blood
pressure [6]. It has been reported that the input of exoge-
nous NO into the vitro organization of mammalian ureters
apparently relaxed ureteral smooth muscle and reduced
muscle tension. It has also been reported that the admin-
istration of adrenergic receptor agonists to the ureteral
tissue can cause detectable increases in NO concentration.
From this, it can be concluded that the relaxing of ureteral
smooth muscle can activate NOS, thus stimulating the
release of NO [7].
In this experiment, we embedded a balloon in the
lower ureter and then progressively expanded it until
complete ureter obstruction was achieved. Then, while
regulating the NOS activity by drugs to affect the release
of NO, we observed the relationship between the pressure
and the concentration of NO in the acutely obstructed
ureter.
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Animals
Healthy adult mixed-breed dogs, 25, were fed individually
and kept in house (at a room temperature of about 26C and
humidity 55%) for about 2 weeks before the experiment
began, to ensure that they had adapted to the local
environment.
Development of the animal model of acute ureteral
obstruction
The animals were anesthetized with sodium pentobarbital
(30 mg/kg, 3%) by intraperitoneal injection. Tracheotomy
was performed immediately, and positive pressure venti-
lation established (frequency of ventilator maintained at 15
times/min, 20 ml/kg). The dogs were secured to the
experimental table and physiological saline (15 ml/kg/h)
was infused intravenously to ensure a stable ﬂow of urine.
Neck incisions were made and expanded and the left
internal carotid artery was used to monitor the invasive
blood pressure and heart rate. A small incision was made
on the left midsection to provide access to the left kidney,
and a small incision was made on the lateral process edge
of the kidney. A catheter of about 5 cm was inserted
through the ureter connecting on one end with a three-way
pipe that in turn connected to the transducer, the transducer
connected to the recorder for monitoring ureter pressure
(UP). A small incision was made on the lower abdomen to
provide access to the bladder and the left ureter. A small
incision was made on the lower ureter nearby the bladder
and insert the amino-600 of about 4 cm, then balloon was
placed no closer to the top of the ureter than 2 cm. We
observed that ureter pressure increased gradually while the
balloon was being inﬂated. When ureter pressure began to
plateau, we observed that the pressure remained unchanged
for about 10 min. This we considered to be a successful
model of ureteral obstruction. Finally, the left ureter was
ligated along the outside wall of the bladder, and a small
incision was made on the ureter under the balloon to insert
a catheter (about 2 mm in diameter) to collect urine leaking
around the balloon (Fig. 1).
Experimental group
After successful establishment of the animal model, the
dogs were randomly divided into ﬁve groups: control group
A( n = 5, isoprenaline 10 lg/kg ? saline) and experi-
mental groups B1 (n = 5, isoprenaline 10 lg/kg ?
L-NAME 5 mg/kg), B2 (n = 5, isoprenaline 10 lg/kg ?
L-NAME 10 mg/kg), B3 (n = 5, isoprenaline 10 lg/kg
? L-NAME 20 mg/kg), and B4 (n = 5, isoprenaline
10 lg/kg ? L-NAME 30 mg/kg).
Administration
First, the models were pre-treated intravenously with dif-
ferent doses of L-NAME (non-selective nitric oxide syn-
thase inhibitor) to inhibit nitric oxide synthase (NOS), and
10 min later, each of them was administered an intravenous
dose of isoproterenol (10 lg/kg). Ureteral pressure and the
concentration of NO in the ureteral urine [the concentration
of NO was monitored with an NO monitor (model inNO-T,
Innovative Instruments)] were measured simultaneously.
Each sensor was calibrated using pure, NO-saturated water.
Brieﬂy, this NO-saturated water was prepared by bubbling
pure NO gas through oxygen-free pure water. Using a gas-
tight syringe, 5 lL of water was injected into well-stirred
saline solution (50 mL) in which the NO sensor was
immersed (ﬁnal NO concentration: 190 nmol). The base-
line (0 level) was set arbitrarily using the amperometric
method, and, thus, it became possible to interpret changes
in the current from the baseline as changes in NO con-
centration (nmol), and in the volume of the urine (UFv)
leaking around the balloon.
Statistical analysis
The data are expressed as mean ± standard deviation
(Mean ± SD). A one-way ANOVA was used for the sta-
tistical analysis of multiple comparisons within each group.
Fig. 1 Measuring the concentration of NO and pressure in the ureter
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123When a signiﬁcant difference was detected, the data were
further analyzed with Dunnett’s test. A Student’s t test for
unpaired data was used when comparisons were made
between two groups. A value of P\0.05 was considered
to indicate statistical signiﬁcance.
Results
The animal models of acute ureteral obstruction were
all created successfully
The equilibrium UP was 52.2 ± 3.6 mmHg (n = 25) and
the time required to reach the equilibrium after ureteral
obstruction was 91.0 ± 3.0 min (n = 25).
Concentration of NO in the acutely obstructed ureters
of different groups
The concentration of NO and the total concentration for
each experimental and control group shown in Fig. 2. After
the administration of isoproterenol, the concentration of
NO gradually increased and reached a peak value. Then,
the concentration of NO gradually diminished, approaching
the starting concentration. However, both the peak value
and the total concentration of NO varied by group: groups
A, B1, and B2 showed the highest values, while group B4
showed the lowest values. The peak values and the total
concentration among groups A, B1, and B2 showed no
statistically signiﬁcant differences (P[0.05) (Fig. 2).
Changes in UP in different groups
About 2 min after the administration of isoproterenol, we
were able to observe the maximum rate of change in the
UP in each group: group A: 67.48 ± 5.62%, group B1:
70.01 ± 5.21%, group B2: 64.34 ± 4.52%, group B3:
54.39 ± 4.44%, group B4: 44.67 ± 2.02%. Groups B3 and
B4 showed signiﬁcantly lower rates of change than groups
A, B1 and B2 did (P\0.05). Group B4’s rate of change
was lower than that of groups B3 (P\0.05), demonstrat-
ing that the rate of change in UP was inversely proportional
to the amount of L-NAME given to each group. However,
there was no statistically signiﬁcant difference (P[0.05)
between groups A, B1, and B2. From the pressure–time
curve shown in Fig. 3, it can be observed that UP declined
rapidly reaching its minimum value about 2 min after the
administration of isoproterenol, then gradually recovered,
ﬁrst at a moderate pace and then more slowly, eventually
holding steady. The time that it took to return to and
maintain a stable level of UP was different for each group,
but directly related to the size of the dose of L-NAME.
Groups B3 and B4 took more time than groups A, B1 or B2
(P\0.05); group B4 took longer than groups B3
(P\0.05). Groups A, B1 and B2 were not signiﬁcantly
different from each other in this respect (P[0.05). We
also observed that during the time that elapsed between the
injection of isoproterenol to the maintenance of a stable
level of UP, the UP of groups B3 and B4 was signiﬁcantly
higher than that of groups A, B1 or B2 (P\0.05) and that
of group B4 was higher than that of group B3 (P\0.05)
but those of groups A, B1 and B2 were not obviously
different from each other (P[0.05) (Fig. 3).
The volume of the urine ﬂow (UFv) leaking
from the balloon in different groups
For every group, the volume of leaked urine was collected
for 20 min before ureteral obstruction was established and
during ﬁve consecutive 20 min periods after obstruction
and injection of L-NAME for a total of 100 min. We
compared measurements of urine ﬂow volume (UFv) from
the unobstructed 20 min and found no statistically signiﬁ-
cant difference between the groups (P[0.05). After the
administration of L-NAME, UFv gradually increased over
time, with the exception that the ﬁrst 20 min post-injection
period saw more leakage than the second 20 min post-
injection period in all groups (P\0.05), the other time
periods: ‘‘the third 20 min post-injection’’, ‘‘the fourth
20 min post-injection’’, and ‘‘the ﬁfth 20 min post-injec-
tion’’ in each group (P\0.05). For every 20 min period
after the injection of L-NAME, UFv was found to be
inversely proportional to the dose L-NAME: groups A, B1,
and B2 showed signiﬁcantly higher UFv than groups B3 or
B4 (P\0.05); and group B3 showed higher UFv than
group B4 (P\0.05); but among groups A, B1, and B2,
there was no statistically signiﬁcant difference (P[0.05)
(Fig. 4).
Discussion
The animal model of acute ureteral obstruction
Acute ureteral obstruction can lead to the changes in
pressure inside the ureter, and then to ureter function dis-
orders. In this experiment, we created an animal model: via
the application of a balloon embedded in the lower ureter,
which was expanded to cause complete ureter obstruction
[8]. This model provides great advantages over previous
techniques [9]. We observed that ureteral pressure
increased gradually alongside the amount of liquid inside
the balloon. In the end, UP reached stable levels in all test
subjects. In this experiment, we observed that the average
of ureter pressure was 52.2 ± 3.6 mmHg (n = 25) when
balanced. The average time it took to reach this level was
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observed that UP could go to a maximum of approximately
120 min without undergoing any changes, which is in
accordance with the previous reports [10, 11]. From this we
can determine that this model creates situations very sim-
ilar to clinical cases of lower ureteral obstruction. In this
model, subjects were pre-treated with different doses of
L-NAME (nitric oxide synthase inhibitor) by intravenous
injection and then given a constant dose of isoprenaline to
stimulate ureteral smooth muscle relaxation. After admin-
istration, we observed changes of the ureteral pressure,
monitored the concentration of NO in ureteral urine using
the inNO-T nitric oxide monitoring system, observed the
relationship between NO concentration and the ureteral
pressure, and learned the role that NO plays in acute
obstructive ureteral recanalization.
The role of NO on the pressure of the acute obstructive
ureter
Morrissey et al. found in an animal experiment that ureteral
pressure increased signiﬁcantly after administration of
Fig. 2 NO concentration in
acutely obstructed ureters in
different groups
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123NOS inhibitors, while the concentration of nitrite in ure-
teral urine was signiﬁcantly lower than normal [12].
However, after administering nitric oxide and synthesis of
L-arginine, they found that the ureteral pressure decreased
signiﬁcantly, and that the concentration of nitrite in ureteral
urine was increased [12]. From this, they speculated that
NOS inhibitors and NOS can regulate the relaxation of
ureteral smooth muscle by altering the concentration of NO
and so control ureteral pressure [12]. Quayle et al. found
that drugs stimulated the ureteral smooth muscle to relax
and that this was caused either by preventing calcium ions
from entering smooth muscle cells or by reducing the
sensitivity of calcium channels [13]. As a result, this
reduced the concentration of calcium ions in the smooth
muscle cells and eased smooth muscle contraction [13].
Iselin et al. found exogenous NO to increase cyclic gua-
nosine monophosphate (cGMP) levels and promote smooth
muscle relaxation in isolated strips of pig ureteral smooth
muscle [14]. Weiss et al. observed that ureteral peristalsis
became signiﬁcantly reduced after administration of nico-
randil, and speculated that this phenomenon may result
from the action of endothelial NOS on the ureter, and the
subsequent increase in NO, that NO inhibited calcium ion
channels, then reduced the concentration of intracellular
calcium ions, then inhibited ureteral smooth muscle con-
tractile function [15]. Holzmann et al. proposed that the
mechanism of this might be that NO ﬁrst diffuses into
smooth muscle cells to activate guanylate cyclase (GC),
which can activate cGMP [16]. High concentrations of
cGMP can activate the K
?–ATP or K
?–Ca
2? channels, and
lead to K
? inﬂux and Ca
2? outﬂow, reducing the concen-
tration of intracellular calcium ions, activating smooth
muscle relaxation. Smooth muscle relaxation itself can
activate NOS, stimulating the release of more NO.
In our experiment, when isoproterenol combined with
adrenergic receptors, it leads to muscle relaxation (there
are afﬂuent adrenergic receptors on canine ureteral smooth
muscle [8], when exposed to b-adrenergic agonists, they
stimulate ureteral smooth muscle relaxation). This then
caused NOS activation and the release of more NO. When
the concentration of NO increased, we extrapolated that the
concentration of cGMP on the ureteral smooth muscle
increased as well. This inhibited calcium ion ﬂow into the
muscle cells, resulting in smooth muscle relaxation and
decrease in ureteral pressure. The more NO, the greater the
range of relaxation observed in the ureteral smooth muscle,
and the greater the decrease in ureteral pressure. When the
ureteral pressure reduced and dropped to a certain level, the
urine will leak out around the edge of the balloon. In this
experiment, we pre-treated subjects from each group with
different doses of L-NAME to inhibit nitric oxide synthase
activation in order to inhibit the release of NO.
Ureteral pressure became steady after the animal model
of acute ureteral obstruction was successfully established,
and the ureteral smooth muscle was in a quiescent state.
During this time, we observed that the concentrations of
NO inside the ureter were very low. However, a certain
period after the injection of isoproterenol, we found that
Fig. 4 Volume of the urine
(UFv, ml) leaking from around
the balloon in different groups
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123the concentration of NO increased sharply in each group.
We speculated that this might be result of activation of
NOS stemming from the isoproterenol combining with
adrenergic receptors. Moreover, we observed that the
greater the dose of L-NAME, the more NOS was inhibited,
and the lower the amount of NO. For example, groups A,
which received no L-NAME, saw the highest peak con-
centration of NO, the greatest total concentration of NO,
and the largest rate of change in ureteral pressure. The
urine leaking around the edge of the balloon was also the
highest in volume. The peak and the total concentrations of
NO, UP, and UFv were not of great difference among
groups B1, B2, and A, all of which received low or no
doses of L-NAME. However, when the pre-treated dose of
L-NAME was larger, such as with groups B3 (20 mg
L-NAME), and B4 (30 mg L-NAME), more nitric oxide
synthase was inhibited, and less NO was released.
According to the theory proposed by Holzmann et al., we
speculated that it (L-NAME) reduced the concentrations of
cGMP when less NO was released, thus inhibiting
K
?–ATP and K
?–Ca
2? channels, and reducing K
? inﬂux
and Ca
2? outﬂow, so that more calcium ions remained in
the muscle cells [16]. As a result, ureteral smooth muscle
relaxation was inhibited, and ultimately the rate of change
in ureteral pressure was minimized, ﬁnally resulting in a
reduction in the amount of urine leaking from the balloon.
The effects of NO on UFv
During the ﬁrst 100 min after the injection of isoprenaline
(10 lg/kg), we found that UFv increased gradually,
showing the least leakage in the second 20 min after the
establishment of the obstruction and more in each 20 min
period after that. It may be that drug-induced smooth
muscle relaxation may cause urine cached above the
obstructed site to drain out. However, because the total
amounts of urine ﬂow in groups B1 (L-NAME 5 mg) and
B2 (L-NAME 10 mg) were greater than those of groups B3
(L-NAME 20 mg) and B4 (L-NAME 30 mg), we specu-
lated that this phenomenon was rather due to the action of
L-NAME as an NOS enzyme inhibitor on nitric oxide
synthase activation, reducing NO release, and resulting in
the largest rate of change in ureteral pressure through
controlling the K
? –ATP or K
? –Ca2
? channels to
inhibit the ureteral smooth muscle relaxation. In the end,
the amount of urine leaking from the balloon was reduced.
Moreover, in this experiment, we observed that the con-
centration of NO was greatest and the rate of change of
ureteral pressure was largest during the ﬁrst 20 min after
injection, while the volume of the urine ﬂow was the
lowest at this time. Probably, the reason for this is that the
UFv in the ﬁrst 20 min had been partially collected from
the remaining before the obstruction.
According to the data recorded during this experiment, it
can be speculated that the relaxation of ureteral muscle and
decreasing ureteral wall tension caused by NO may pro-
mote urine ﬂow around incarcerated calculi. There may be
decreased force of coaptation between the point of
obstruction and the ureteral wall, which may actually
decrease the pressure gradient across the obstructed site.
This avenue of urine ﬂow can cause a drop in UP or even
permit passage of a kidney stone.
Conclusion
In general, the pressure in an acutely obstructed ureter and
the concentration of NO released by the nearby tissue will
be inversely proportional to one another. The greater the
concentration of NO, the greater the rate of change in
ureteral pressure. In clinical situations, we have often
encountered patients with acutely painful ureteral stones.
We believe that taking measures to quickly increase the
concentration of NO inside the ureter would reduce the
pressure inside ureter and cause the stone to be discharged.
It is even possible that the administration of drugs to
stimulate the relaxation of ureteral smooth muscle and the
release of NO may facilitate the residual stones to dis-
charge after ureteroscopic lithotripsy or extracorporeal
shock wave lithotripsy. Nevertheless, because this is only
an animal experiment, at present, clinical evidence is still
lacking. Effective drugs that solely and speciﬁcally
increase the concentration of NO inside the human ureter
particularly drugs that do not affect the cardiovascular
system have yet to be identiﬁed and conﬁrmed. Further
study is needed to establish to any useful degree.
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